Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...
Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
How the ‘Oxford’ Covid-19 vaccine became the ‘AstraZeneca’ Covid-19 vaccine
The ‘Oxford / AstraZeneca’ vaccine is one of the world’s leading hopes in the race to end the Covid-19 pandemic. Its history is not...
The European Parliament has now explicitly acknowledged the know-how problem too: time to include...
This technical briefing note is also available as a PDF here.
We have been calling attention to the problem of sharing know-how necessary for the...
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic, India...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
What is the ‘know-how gap’ problem and how might it impact scaling up production...
This entire article is also available as a PDF by clicking here.
1. Introduction.
How relevant are concerns about intellectual property rights causing problems for...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
The EU proposed Covid waivers of certain TRIPS rules are mostly meaningless
Since October 2020, discussions have been ongoing at the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council about a waiver of...
European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and...
European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...